Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... TRIANGLE PARK, N.C. and ... agricultural research firm AgBiome, and Genective, key developer ... to accelerate the discovery of new generations of ... traits for insect control to counter the realities ... partner with Genective, aligning AgBiome,s unique insect control ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
(Date:6/30/2015)... Japan , July 1, 2015 R-Japan Co.,Ltd. ... on the Safety of Regenerative Medicine from the Ministry of ... on June 29, 2015. The fact that ... processing facility through the auditing from Pharmaceuticals and Medical Devices ... the application, allows it to provide stem cell manufacturing service ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... , PALO ALTO, Calif., Aug. 17, 2009 ... with a focus on the NS4B Hepatitis C Virus (HCV) ... Board of Directors. , , Truex is ... private pharmaceutical company focused on the development of anti-inflammatory products ...
... , SAN DIEGO, Aug. 17 Imagenetix, ... natural-based, proprietary products announced that last week Dr. Robert Hesslink, ... on his Bloomberg Radio program, Taking Stock. Dr. Hesslink ... its flagship product, InflameAway Celadrin(R), and 1-TDC, Imagenetix,s early stage ...
... Inc. (NASDAQ: VSGN ; TSX:VAS), today announced that ... Department of The NASDAQ Stock Market indicating that Vasogen ... We plan to request a hearing before the NASDAQ ... determination of the continued listing of our common stock. ...
Cached Biology Technology:Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors 2Imagenetix, Inc. Announces Interview With Bloomberg Radio 2Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... CORVALLIS, Ore. A laboratory study has shown for the ... are linked to a side-effect of some statin drugs - ... of the most widely prescribed drugs in the world, able ... of heart attacks or other cardiovascular events. However, their role ...
... dozen Ludwig scientists from around the world presented the ... this week,s American Association for Cancer Research (AACR) Annual ... program with important diagnostic and treatment implications for emerging ... available to help patients with melanoma, researchers are developing ...
... age at which a child with autism is diagnosed ... he or she exhibits, new research from the University ... poor nonverbal communication and repetitive behaviors, were associated with ... a study in the April issue of the ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting 2In autism, age at diagnosis depends on specific symptoms 2